These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 21988129)
1. Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6/1 Huntington's disease mice. Hannan AJ; Ransome MI J Neuroendocrinol; 2012 Feb; 24(2):341-56. PubMed ID: 21988129 [TBL] [Abstract][Full Text] [Related]
2. Impaired basal and running-induced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice. Ransome MI; Hannan AJ Mol Cell Neurosci; 2013 May; 54():93-107. PubMed ID: 23384443 [TBL] [Abstract][Full Text] [Related]
3. Physical activity fails to rescue hippocampal neurogenesis deficits in the R6/2 mouse model of Huntington's disease. Kohl Z; Kandasamy M; Winner B; Aigner R; Gross C; Couillard-Despres S; Bogdahn U; Aigner L; Winkler J Brain Res; 2007 Jun; 1155():24-33. PubMed ID: 17512917 [TBL] [Abstract][Full Text] [Related]
4. The influence of the HPG axis on stress response and depressive-like behaviour in a transgenic mouse model of Huntington's disease. Du X; Pang TY; Mo C; Renoir T; Wright DJ; Hannan AJ Exp Neurol; 2015 Jan; 263():63-71. PubMed ID: 25246229 [TBL] [Abstract][Full Text] [Related]
5. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice. Mo C; Renoir T; Hannan AJ Neurobiol Dis; 2014 Nov; 71():81-94. PubMed ID: 25088714 [TBL] [Abstract][Full Text] [Related]
6. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Smith KM; Matson S; Matson WR; Cormier K; Del Signore SJ; Hagerty SW; Stack EC; Ryu H; Ferrante RJ Biochim Biophys Acta; 2006 Jun; 1762(6):616-26. PubMed ID: 16647250 [TBL] [Abstract][Full Text] [Related]
7. Progressive imbalance in the interaction between spatial and procedural memory systems in the R6/2 mouse model of Huntington's disease. Ciamei A; Morton AJ Neurobiol Learn Mem; 2009 Oct; 92(3):417-28. PubMed ID: 19524696 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609 [TBL] [Abstract][Full Text] [Related]
9. Early retinal function deficit without prominent morphological changes in the R6/2 mouse model of Huntington's disease. Ragauskas S; Leinonen H; Puranen J; Rönkkö S; Nymark S; Gurevicius K; Lipponen A; Kontkanen O; Puoliväli J; Tanila H; Kalesnykas G PLoS One; 2014; 9(12):e113317. PubMed ID: 25469887 [TBL] [Abstract][Full Text] [Related]
10. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. Murphy KP; Carter RJ; Lione LA; Mangiarini L; Mahal A; Bates GP; Dunnett SB; Morton AJ J Neurosci; 2000 Jul; 20(13):5115-23. PubMed ID: 10864968 [TBL] [Abstract][Full Text] [Related]
11. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Mihm MJ; Amann DM; Schanbacher BL; Altschuld RA; Bauer JA; Hoyt KR Neurobiol Dis; 2007 Feb; 25(2):297-308. PubMed ID: 17126554 [TBL] [Abstract][Full Text] [Related]
12. Weight loss in Huntington disease increases with higher CAG repeat number. Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372 [TBL] [Abstract][Full Text] [Related]
13. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Milnerwood AJ; Cummings DM; Dallérac GM; Brown JY; Vatsavayai SC; Hirst MC; Rezaie P; Murphy KP Hum Mol Genet; 2006 May; 15(10):1690-703. PubMed ID: 16600988 [TBL] [Abstract][Full Text] [Related]
14. Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease. Choi ML; Begeti F; Oh JH; Lee SY; O'Keeffe GC; Clelland CD; Tyers P; Cho ZH; Kim YB; Barker RA Neurobiol Dis; 2014 Jun; 66():19-27. PubMed ID: 24561069 [TBL] [Abstract][Full Text] [Related]
15. Retinal dysfunction, photoreceptor protein dysregulation and neuronal remodelling in the R6/1 mouse model of Huntington's disease. Batcha AH; Greferath U; Jobling AI; Vessey KA; Ward MM; Nithianantharajah J; Hannan AJ; Kalloniatis M; Fletcher EL Neurobiol Dis; 2012 Mar; 45(3):887-96. PubMed ID: 22198376 [TBL] [Abstract][Full Text] [Related]
16. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease. Dufour BD; McBride JL Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559 [TBL] [Abstract][Full Text] [Related]
17. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. Papalexi E; Persson A; Björkqvist M; Petersén A; Woodman B; Bates GP; Sundler F; Mulder H; Brundin P; Popovic N Eur J Neurosci; 2005 Sep; 22(6):1541-6. PubMed ID: 16190907 [TBL] [Abstract][Full Text] [Related]
18. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice. Zajac MS; Pang TY; Wong N; Weinrich B; Leang LS; Craig JM; Saffery R; Hannan AJ Hippocampus; 2010 May; 20(5):621-36. PubMed ID: 19499586 [TBL] [Abstract][Full Text] [Related]
19. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Grote HE; Bull ND; Howard ML; van Dellen A; Blakemore C; Bartlett PF; Hannan AJ Eur J Neurosci; 2005 Oct; 22(8):2081-8. PubMed ID: 16262645 [TBL] [Abstract][Full Text] [Related]
20. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease. Dufour BD; McBride JL Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]